When Patients Move Without Us
Patients do not wait for institutional consensus. They do not suspend action while guidelines are debated. When access expands — whether to supplements, online prescriptions, new procedures, or medical cannabis — behavior follows.
The question is not whether patients will seek these options.
The question is whether we will be present when they do.
In states with medical cannabis programs, patients are already using it. Some do so openly. Others do so quietly. Many are attempting to manage symptoms that have not fully responded to conventional treatment. Some are thoughtful and cautious. Others are navigating information from dispensaries, online forums, or word of mouth. What unites them is not ideology. It is unmet need.
Physicians can choose to disengage from this reality. That disengagement often comes from understandable places: institutional risk aversion, discomfort with evolving evidence, lack of training, fear of professional scrutiny. These hesitations are not irrational.
But opting out does not prevent use.
It simply removes medical supervision from the equation.
When physicians withdraw, the vacuum does not remain empty. It fills with high-volume certification services operating at the margins of longitudinal care. It fills with loosely structured encounters disconnected from a patient's broader medical history. Patients still obtain cannabis. They simply do so without integration, without meaningful documentation, and without coordinated oversight.
That fragmentation should concern us more than the substance itself.
Regulated medical cannabis systems, imperfect as they are, offer traceability, product testing, dispensary oversight, and in many states, prescription monitoring integration. Purchases are logged. Patterns are visible. There is at least the possibility of supervision.
Supervision matters.
Not because cannabis is universally appropriate — it is not. Not because it replaces established treatments — it does not. But because harm reduction is a legitimate medical stance when behavior is inevitable.
We already apply this logic elsewhere. We counsel patients about alcohol use without assuming abstinence. We manage opioid dependence through structured programs rather than moral distance. We prescribe medications with misuse potential because untreated suffering carries risk as well.
And yet, when it comes to medical cannabis, many physicians feel forced into a false binary: endorse or disengage.
There is another path.
Participation does not mean indiscriminate approval. It means evaluation. It means reviewing psychiatric history, current medications, risk factors, and expectations. It means documenting rationale and discussing uncertainties. It means declining when appropriate — but doing so within relationship, not from a distance.
In psychiatry specifically, that evaluation carries particular weight. Many patients seeking medical cannabis certification in Virginia are managing conditions — anxiety, PTSD, treatment-resistant depression, sleep disorders, or chronic pain with significant mood components — that intersect directly with existing psychiatric medication regimens. The question of whether cannabis is appropriate cannot be answered in isolation from that pharmacological context. What other medications is the patient taking? Is the current psychiatric presentation stable enough to introduce a new variable and assess its effect with any accuracy? Is the anticipated benefit realistic given the actual evidence base for this specific patient and condition? These are not abstract questions. They are precisely the questions a physician with access to a patient's longitudinal psychiatric record is positioned to ask. A medical cannabis certification encounter disconnected from that record is not a clinical evaluation. It is documentation of an intention.
Institutional constraints are real. Many physicians work in systems that discourage direct involvement. Liability concerns are not trivial. But in many regions, when physicians opt out, there are no well-integrated referral pathways to send patients to. What remains are certification mills and fragmented services that operate without coordination with primary teams. That absence is not inevitable.
It is a design failure.
If institutions cannot absorb this work directly, they should support structured referral relationships with accountable, physician-led clinicians who prioritize documentation, communication, and integration into the broader medical record. Supervision does not require personal endorsement; it requires refusing to let patient behavior occur in isolation.
When we withdraw without building alternatives, we do not eliminate risk. We shift it. Patients move forward anyway — just without coordinated oversight. That is not neutrality. It is absence.
The psychiatric consequences of that absence are specific. Cannabis can precipitate or worsen psychotic symptoms in genetically vulnerable individuals. It can destabilize mood regulation in patients with bipolar disorder. It interacts with the CNS depressant profile of many commonly prescribed psychiatric medications. In patients with trauma histories, high-THC products carry a different risk profile than they do in the general population. These are not arguments against access. They are arguments for integration — for making cannabis use visible to the clinician managing a patient's psychiatric care, rather than a variable that accumulates silently outside the medical record.
If we believe fragmented care contributes to drift, then disengagement in this arena only accelerates it. When cannabis use is siloed from primary care and psychiatry, it becomes one more variable that is poorly tracked and poorly understood.
When it is integrated into the clinical conversation, it becomes part of the medical narrative rather than a parallel one. Patients deserve clinicians who are willing to sit in ambiguity with them — not disappear from it. Medicine does not protect patients by pretending behavior will stop. It protects them by showing up when it does not.
Showing up, in this context, means something specific. It means a clinician who conducts a real evaluation before any certification is completed — reviewing the psychiatric history, the current treatment plan, the risk factors, and the realistic evidence base — and who remains accessible as the patient's experience unfolds. In Virginia, where a telehealth psychiatrist practicing statewide can provide that kind of integrated, physician-led oversight to patients who might not otherwise have access to it, the infrastructure already exists. The question is whether we are willing to use it deliberately, rather than cede the space to high-volume services that treat certification as the endpoint rather than the beginning of a clinical relationship.
